cutaneous t cell lymphoma, maintenance treatment, resminostat, HDAC inhibitor
Relapsed/Refractory DLBCL, Non-Hodgkin Lymphoma, Polatuzumab Vedotin, Lenalidomide, Circulating Tumour DNA